Human eggs that contain too many or too few chromosomes can lead to miscarriage, IVF failure and conditions such as Down’s syndrome. Now, researchers have found that giving the eggs a single injection can substantially reduce the problem. The approach could eventually boost the chances of success for older women undergoing IVF.

“It really seems like a big deal,” says at Nilo Frantz Reproductive Medicine in Porto Alegre, Brazil, who wasn’t involved in the new research. “To my knowledge, this is the first [therapy] to show such clinical potential for correcting this major cause of IVF failure.”

During a process called meiosis, egg and sperm cells eject exactly half of their genetic material. This means that when egg and sperm combine during fertilisation, they form an embryo with a complete genome. Sometimes, however, a sperm or egg cell has slightly more or slightly less than the half genome it should contain. This is a condition known as aneuploidy.

Aneuploidy affects about in the early 30s and becomes more common with age. “Already in the late 30s, more than 65 per cent of all eggs are aneuploid,” at Ovo Labs, a biotechnology company in Germany, told the audience at the conference in London on 6 July.

Clinicians sometimes screen IVF embryos for aneuploidy when treating couples at greater risk of miscarriage or IVF failure. , conditions caused by the genetic error – which include Down’s syndrome – are only detected via blood tests and ultrasound scans taken during the first trimester of pregnancy. Until now, there have been no ways to reduce the risk of aneuploidy occurring in the first place, says Zielinska.

Now, Zielinska and her colleagues have found that the level of a protein called shugoshin-1 is substantially lower in older mouse and human eggs than in younger ones. Shugoshin-1 helps with a stage of meiosis in which two copies of each chromosome line up along the middle of an immature egg cell. The protein maintains the molecular glue that holds each pair together.

Free newsletter

Sign up to Eight Weeks to a ÎçŇą¸ŁŔű1000ĽŻşĎier You

Sign up to newsletter

Upon fertilisation, the two copies of the chromosomes separate and move to opposite sides of the cell. One end ultimately forms the mature egg cell, and the other end is discarded.

But in older eggs, the glue holding the chromosome pairs together degrades, which can cause the two copies of each chromosome to separate before fertilisation. When this happens, the chromosomes spread unevenly throughout the cell – which means the resulting egg may be aneuploid.

To explore whether replenishing shugoshin-1 could prevent aneuploidy by helping to hold chromosome pairs together, the team collected 111 spare, immature eggs from more than 30 women aged between 22 and 43 who were banking eggs or undergoing IVF.

The team injected the genetic code for shugoshin-1, in the form of mRNA, into one or more of each donor’s eggs, and left other eggs from the same donor untreated.

A few hours later, chromosomes had prematurely separated in 53 per cent of the untreated eggs, whereas this figure was nearly half – 29 per cent – in the treated ones. In eggs from nine donors who were aged over 35, aneuploidy rates were 65 per cent, on average, in untreated eggs. But in treated eggs, the average figure was just 44 per cent. This reduction wasn’t statistically significant, although this is probably because of the study’s small sample size, according to the researchers.

Common IVF test misses some genetic abnormalities in embryos

Human embryos formed with in vitro fertilisation can develop genetic abnormalities in the time between genetic testing and implantation – though this may not affect their viability

Further experiments showed the approach could prevent aneuploidy in mouse eggs, which were then successfully fertilised to produce healthy offspring.

No side effects were seen in the mouse or human studies. “We’ve achieved live births in mice, so, from that perspective, we’re confident that this approach is not interfering in the mouse model with any steps of embryo development, and it doesn’t interfere with pup health and pregnancy health,” Zielinska told the conference audience.

The researchers are now working towards testing the effects of shugoshin-1 in people. This would involve tweaking standard IVF to use immature eggs rather than mature ones, but this change would be fairly easy to implement, says Zielinska.

She hopes the therapy, which the team calls EmbryoProtect, will provide an affordable way to improve IVF for older women. “We anticipate that the treatment will cost a fraction of the cost of a full IVF cycle,” says Zielinska. “By meaningfully improving IVF success rates, especially for women over 35 where baseline success is low, we hope that fewer attempts will be needed to conceive.”

A daily pill doubles the survival time of people with pancreatic cancer, one of the most aggressive and difficult-to-treat forms of the condition, even after they have stopped responding to chemotherapy. What’s more, the convenient pill has fewer side effects than standard chemotherapy.

“It’s a transformative treatment,” says at University College London, who wasn’t involved in the research. “For decades, [survival outcomes] haven’t changed for pancreatic cancer. [The new treatment] gives you double the amount of time to enjoy your life, be with your family and do things that you would like to do.”

About 70 per cent of people with pancreatic cancer . A combination of no routine screening and vague symptoms, like a sore back, means that the condition is usually spotted when it has spread elsewhere. Standard treatment involves chemotherapy, but even then, most people only survive for about , on average. “The disease is really aggressive and difficult to treat,” says Acedo.

More than 90 per cent of pancreatic cancers are driven by mutations in the KRAS gene, which encodes for a protein known as K-Ras. When the gene is mutated, K-Ras gets stuck in a state that drives cancer cells to divide uncontrollably.

at Memorial Sloan Kettering Cancer Center in New York and her colleagues wondered if a drug called daraxonrasib, which binds to the protein, could dampen its signals and slow the growth of cancer cells.

So the team recruited 500 people with metastatic pancreatic cancer from the US, Europe and Asia, all of whom had stopped responding to an initial round of chemotherapy. They were assigned to two groups: the first took daraxonrasib every day and the second continued to receive standard chemotherapy infusions.

Free newsletter

Sign up to ÎçŇą¸ŁŔű1000ĽŻşĎ Check

Sign up to newsletter

The researchers – who presented at the American Society of Clinical Oncology meeting in Chicago on 31 May – found that the participants in the daraxonrasib group went on to survive for 13.2 months, on average, compared with 6.7 months in the chemotherapy group. “It’s fantastic news,” says Acedo. The treatment is the first in decades to improve survival outcomes among patients with advanced pancreatic cancer, she says.

What’s more, only 1 per cent of the participants in the daraxonrasib group stopped taking the drug due to side effects, such as rash, whereas 11 per cent stopped chemotherapy due to adverse events like fatigue. “A daily pill is also much easier to take than chemotherapy, which involves frequent hospital visits and is invasive,” says Acedo.

Inside the revolutionary idea that we can negotiate with cancer

New research tapping into decades-old concepts is challenging the notion that the only way to treat cancer is to kill every last cancer cell. Instead, scientists suggest, we could try a little persuasion

The team has submitted the findings to the US Food and Drug Administration, and hopes to get the drug approved for use in people with metastatic pancreatic cancer who have had chemotherapy in the coming months, says O’Reilly.

But it is still far from a cure, says Acedo. “It’s a few extra months, which is really promising, but it’s still not years and they’re still dying of the disease,” says Acedo. Nevertheless, further studies may reveal that combining daraxonrasib with other experimental drugs or chemotherapy could lead to even better outcomes, she says.

The researchers are exploring this in ongoing trials, says O’Reilly. They are also looking at whether daraxonrasib could be used as a first-line therapy in untreated patients, she says.